Stocks and Investing Stocks and Investing
Wed, May 4, 2022

David Amsellem Downgraded (TEVA) to Sell and Decreased Target to $7 on, May 4th, 2022


Published on 2024-10-27 20:50:02 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Sell and Decreased Target from $11 to $7 on, May 4th, 2022.

David has made no other calls on TEVA in the last 4 months.



There are 2 other peers that have a rating on TEVA. Out of the 2 peers that are also analyzing TEVA, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jasper Hellweg of "Argus Research" Downgraded from Strong Buy to Hold on, Thursday, January 27th, 2022


This is the rating of the analyst that currently disagrees with David


  • Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
Contributing Sources